Analyst Viewpoint
Increase in cases of road accidents and rise in prevalence of chronic diseases are driving the hemostatic agents market trajectory. Hemostatic materials are prepared in various forms for wound care applications based on the active ingredients used.
Rise in number surgeries and surge in adoption of minimally invasive surgeries are also fueling the hemostatic agents industry expansion.
Key players are introducing cutting-edge solutions that improve the precision, effectiveness, and accessibility of hemostasis agents.
They are also developing hemostatic medical devices utilizing proprietary gel technologies. Vendors are offering advanced hemostatic agents for surgical applications in human and animal health sectors.
Hemostasis is a process that stops bleeding or blood flow through a blood vessel, or hemorrhage. Hemostasis is a process by which a clot is formed in the injured area, thereby repairing the blood vessels.
Hemostatic agents are utilized to stem blood flow via the increased promotion of clotting, thereby improving the hemostasis by accelerating the coagulation process.
Hemostatic agents play a vital role in the treatment or prevention of bleeding, thereby indicating their usage in various therapeutic areas.
| Attribute | Detail |
|---|---|
| Drivers |
|
Hemostasis agents are mainly utilized to reduce blood flow via the increased promotion of clotting. By improving the body's normal clotting process, these medication minimizes the chance of severe blood loss and enhance patients' condition. These are important in emergency medical scenarios where treating the injury or stopping bleeding is crucial.
Increase in number of road accidents is anticipated to spur the hemostatic agents market growth in the near future.
According to a report published by the Government of India, a total of 461,312 road accidents occurred in the country as per official records. Road accidents often require emergency treatments due to serious injuries.
Surge in number of surgeries and improved access to healthcare facilities are driving the hemostatic agents market value. In 2020, a study published in the International Journal of Surgery reported that 310 million major procedures are performed globally each year, with 20 million in Europe and 40 to 50 million in the U.S.
The International Society on Thrombosis and Hemostasis 2022 report stated that there are roughly 10 million cases of venous thromboembolism globally each year. The same source states that 544,000 deaths in Europe each year are attributed to deep vein thrombosis (DVT).
According to the 2022 Report: Disorders of The Blood, over 3.2 million people in the U.S. suffer from a bleeding disorder every year. Thus, rise in number of patients with blood disorders is fueling the market revenue.
Increase in geriatric population is also augmenting the demand for hemostasis agents as the aging population is more likely to develop chronic illnesses and need various types of surgeries.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest hemostatic agents market analysis, North America held largest share in 2022. Presence of key players and rise in number of surgical procedures are propelling the market dynamics of the region. Surge in funding for clinical research and development by public and private organizations is also contributing to the hemostatic agents industry share in North America.
According to the U.S. Census Bureau, the number of senior people residing in the U.S. in 2021 was over 55 million, representing 17.1% of the overall population. By 2050, the percentage of adults in the country who are 65 years of age or older is expected to increase to around 22% of the total population.
Thus, growth in elderly population is projected to boost the demand for minimally invasive surgical procedures, thereby augmenting the hemostatic agents market size in North America.
Key players operating in the global hemostatic agents market are concentrating on providing a wide range of options for treating excessive blood flow during severe injuries or surgeries.
They are also introducing cutting-edge solutions that improve the precision, effectiveness, and accessibility of hemostatic agents, as well as forging strategic alliances and growing their global footprint.
Baxter, Ethicon, Inc., BD, B. Braun SE, Pfizer, Inc., Teleflex Incorporated, CryoLife, Inc., Integra LifeScience, Advanced Medical Solutions Group plc, and GELITA AG are some of the key players in the hemostatic agents market.
These companies have been profiled in the hemostatic agents market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 2.6 Bn |
| Market Forecast (Value) in 2031 | US$ 4.5 Bn |
| Growth Rate (CAGR) | 6.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 2.6 Bn in 2022
It is anticipated to grow at a CAGR of 6.2% from 2023 to 2031
Increase in cases of road accidents and rise in prevalence of chronic diseases
North America was the leading region in 2022
Baxter, Ethicon, Inc., BD, B. Braun SE, Pfizer, Inc., Teleflex Incorporated, CryoLife, Inc., Integra LifeScience, Advanced Medical Solutions Group plc, and GELITA AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hemostatic Agents Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hemostatic Agents Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hemostatic Agents Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017-2031
6.3.1. Active Agents
6.3.2. Passive Agents
6.3.3. Combination
6.4. Market Attractiveness Analysis, by Product Type
7. Global Hemostatic Agents Market Analysis and Forecast, by Specialty / Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031
7.3.1. Cardiology
7.3.2. Cath Lab
7.3.3. Trauma
7.3.4. General Surgery
7.3.5. ObGyn
7.3.6. Transplant
7.3.7. Oncology
7.3.8. Neurology
7.3.9. Orthopedic
7.3.10. Plastic Surgery
7.3.11. Dental
7.3.12. Others
7.4. Market Attractiveness Analysis, by Specialty / Therapeutic Area
8. Global Hemostatic Agents Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Large Hospital (500+ Beds)
8.3.2. Medium Hospital (250-499 Beds)
8.3.3. Small Hospitals (Less than 250 Beds)
8.4. Market Attractiveness Analysis, by Specialty / Therapeutic Area
9. Global Hemostatic Agents Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Hemostatic Agents Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2017-2031
10.3.1. Active Agents
10.3.2. Passive Agents
10.3.3. Combination
10.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031
10.4.1. Cardiology
10.4.2. Cath Lab
10.4.3. Trauma
10.4.4. General Surgery
10.4.5. ObGyn
10.4.6. Transplant
10.4.7. Oncology
10.4.8. Neurology
10.4.9. Orthopedic
10.4.10. Plastic Surgery
10.4.11. Dental
10.4.12. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
10.5.1. Large Hospital (500+ Beds)
10.5.2. Medium Hospital (250-499 Beds)
10.5.3. Small Hospitals (Less than 250 Beds)
10.6. Market Value Forecast, by Country, 2017-2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Specialty / Therapeutic Area
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Hemostatic Agents Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2017-2031
11.3.1. Active Agents
11.3.2. Passive Agents
11.3.3. Combination
11.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031
11.4.1. Cardiology
11.4.2. Cath Lab
11.4.3. Trauma
11.4.4. General Surgery
11.4.5. ObGyn
11.4.6. Transplant
11.4.7. Oncology
11.4.8. Neurology
11.4.9. Orthopedic
11.4.10. Plastic Surgery
11.4.11. Dental
11.4.12. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
11.5.1. Large Hospital (500+ Beds)
11.5.2. Medium Hospital (250-499 Beds)
11.5.3. Small Hospitals (Less than 250 Beds)
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Specialty / Therapeutic Area
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Hemostatic Agents Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2017-2031
12.3.1. Active Agents
12.3.2. Passive Agents
12.3.3. Combination
12.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031
12.4.1. Cardiology
12.4.2. Cath Lab
12.4.3. Trauma
12.4.4. General Surgery
12.4.5. ObGyn
12.4.6. Transplant
12.4.7. Oncology
12.4.8. Neurology
12.4.9. Orthopedic
12.4.10. Plastic Surgery
12.4.11. Dental
12.4.12. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
12.5.1. Large Hospital (500+ Beds)
12.5.2. Medium Hospital (250-499 Beds)
12.5.3. Small Hospitals (Less than 250 Beds)
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Specialty / Therapeutic Area
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Hemostatic Agents Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2017-2031
13.3.1. Active Agents
13.3.2. Passive Agents
13.3.3. Combination
13.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031
13.4.1. Cardiology
13.4.2. Cath Lab
13.4.3. Trauma
13.4.4. General Surgery
13.4.5. ObGyn
13.4.6. Transplant
13.4.7. Oncology
13.4.8. Neurology
13.4.9. Orthopedic
13.4.10. Plastic Surgery
13.4.11. Dental
13.4.12. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
13.5.1. Large Hospital (500+ Beds)
13.5.2. Medium Hospital (250-499 Beds)
13.5.3. Small Hospitals (Less than 250 Beds)
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Specialty / Therapeutic Area
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Hemostatic Agents Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2017-2031
14.3.1. Active Agents
14.3.2. Passive Agents
14.3.3. Combination
14.4. Market Value Forecast, by Specialty / Therapeutic Area, 2017-2031
14.4.1. Cardiology
14.4.2. Cath Lab
14.4.3. Trauma
14.4.4. General Surgery
14.4.5. ObGyn
14.4.6. Transplant
14.4.7. Oncology
14.4.8. Neurology
14.4.9. Orthopedic
14.4.10. Plastic Surgery
14.4.11. Dental
14.4.12. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
14.5.1. Large Hospital (500+ Beds)
14.5.2. Medium Hospital (250-499 Beds)
14.5.3. Small Hospitals (Less than 250 Beds)
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Specialty / Therapeutic Area
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Baxter
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Ethicon, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. BD
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. B. Braun SE
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Pfizer, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Teleflex Incorporated
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. CryoLife, Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Integra LifeSciences
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Advanced Medical Solutions Group plc
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. GELITA AG
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 02: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031
Table 03: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Hemostatic Agents Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 07: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031
Table 08: North America Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 11: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031
Table 12: Europe Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 15: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031
Table 16: Asia Pacific Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 19: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031
Table 20: Latin America Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Product Type, 2017-2031
Table 23: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Specialty / Therapeutic Area, 2017-2031
Table 24: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Hemostatic Agents Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
Figure 02: Global Hemostatic Agents Market Revenue (US$ Mn), by Product Type, 2022
Figure 03: Global Hemostatic Agents Market Value Share, by Product Type, 2022
Figure 04: Global Hemostatic Agents Market Revenue (US$ Mn), by Specialty / Therapeutic Area, 2022
Figure 05: Global Hemostatic Agents Market Value Share, by Specialty / Therapeutic Area, 2022
Figure 06: Global Hemostatic Agents Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Hemostatic Agents Market Value Share, by Distribution Channel, 2022
Figure 08: Global Hemostatic Agents Market Value Share, by Region, 2022
Figure 09: Global Hemostatic Agents Market Value (US$ Mn) Forecast, 2017-2031
Figure 10: Global Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031
Figure 11: Global Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 12: Global Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031
Figure 13: Global Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031
Figure 14: Global Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 15: Global Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Hemostatic Agents Market Value Share Analysis, by Region, 2022-2031
Figure 17: Global Hemostatic Agents Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Hemostatic Agents Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Hemostatic Agents Market Value Share Analysis, by Country, 2022-2031
Figure 21: North America Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031
Figure 22: North America Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031
Figure 23: North America Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 24: North America Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 25: North America Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031
Figure 26: North America Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 28: Europe Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 30: Europe Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031
Figure 31: Europe Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031
Figure 32: Europe Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 33: Europe Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 34: Europe Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031
Figure 35: Europe Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 36: Asia Pacific Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 37: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 39: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031
Figure 40: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031
Figure 41: Asia Pacific Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 42: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 43: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031
Figure 44: Asia Pacific Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 45: Latin America Hemostatic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 46: Latin America Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 47: Latin America Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 48: Latin America Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031
Figure 49: Latin America Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031
Figure 50: Latin America Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 51: Latin America Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 52: Latin America Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031
Figure 53: Latin America Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 54: Middle East & Africa Hemostatic Agents Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 55: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Country/Sub-region, 2022-2031
Figure 57: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Product Type, 2022-2031
Figure 58: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Specialty / Therapeutic Area, 2022-2031
Figure 59: Middle East & Africa Hemostatic Agents Market Value Share Analysis, by Distribution Channel, 2022-2031
Figure 60: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 61: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Specialty / Therapeutic Area, 2023-2031
Figure 62: Middle East & Africa Hemostatic Agents Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hemostatic Agents Market
*86 figures and 60 tables includes